admin – Page 5532 – Get News Story

Soft Tissue Sarcoma Market is expected to grow at a significant CAGR, DelveInsight | Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm

“Soft Tissue Sarcoma Market”

As per DelveInsight, the Soft Tissue Sarcoma Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Soft Tissue Sarcoma in the 7MM. The emergence of new products in the pipeline is expected to drive growth in the soft tissue sarcoma market. The ongoing rise in soft tissue sarcoma cases throughout the forecast period will further contribute to the expansion of the soft tissue sarcoma treatment market.

DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Soft Tissue Sarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Soft Tissue Sarcoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Key highlights from the Soft Tissue Sarcoma Market Report:

DelveInsight’s analysis forecasts significant growth in the soft tissue sarcoma market, with a robust Compound Annual Growth Rate (CAGR) expected by 2032.
According to updated statistics from the American Cancer Society (2022), there were approximately 13,190 new cases of soft tissue sarcoma in the US, along with around 5,130 deaths (2,740 males and 2,390 females) attributed to the disease.
Leading soft tissue sarcoma companies such as Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others are developing novel soft tissue sarcoma drugs that can be available in the soft tissue sarcoma market in the coming years.
Some of the key therapies for soft tissue sarcoma treatment include Camsirubicin, Lurbinectedin, Liposomal Annamycin (L-Annamycin), AL3818, YH001, CFT8634, Olaratumab + Doxorubicin, Tazemetostat + Doxorubicin HCl, Niraparib, Seclidemstat, Tinostamustine (EDO-S101), HFB301001, Tigilanol Tiglate, Pembrolizumab, Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy, L19TNF and DOXORUBICIN, doxorubicin with AGEN1884 and AGEN2034, APX005M, MGCD516, and others.
In August 2024, the Food and Drug Administration (FDA) approved a cellular therapy called afamitresgene autoleucel, or afami-cel (Tecelra), to treat some people with metastatic synovial sarcoma, a type of soft tissue sarcoma. The decision marks the first time the agency has approved a treatment called a T-cell receptor (TCR) therapy for cancer.
In March 2024, Lamassu awarded a grant from the NIH and NCI forthe development of their groundbreaking treatment for p53 wildtype sarcomas. The company focuses on advancing SA53, a noveltherapeutic that targets p53 wild-type sarcomas, malignant tumorsof connective or non-epithelial tissue.
In February 2024, Philogen provided an update on pre-plannedinterim analysis of the Phase III FIBROSARC trial investigatingOnfekafusp alfa (L19TNF) in patients with first-line advanced ormetastatic STS.
In Feb 2024, QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, was awarded Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) by the United States Food and Drug Administration (FDA).

Read detailed insights on Soft Tissue Sarcoma market outlook 2032 @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market

Soft Tissue Sarcoma Overview

Soft tissue sarcoma is a relatively uncommon cancer that develops in the body’s soft tissues, including muscles, tendons, fat, blood vessels, and nerves. While it can affect individuals of any age, it is more frequently diagnosed in adults. The precise causes of soft tissue sarcoma are not always well understood, but certain risk factors have been identified, such as exposure to radiation, specific genetic conditions, and previous treatment with certain chemotherapy drugs.

Symptoms of soft tissue sarcoma vary depending on the tumor’s location and size. Common signs include a noticeable lump or swelling in the affected area, pain or tenderness, restricted movement, and sometimes a sensation of pressure or fullness. Because these symptoms can also indicate other conditions, it is important to consult a healthcare professional if they persist or worsen.

Diagnosis typically involves a combination of imaging tests—such as MRI, CT scans, and ultrasounds—to locate and assess the tumor. A biopsy is then performed, where a small sample of tissue is taken and examined microscopically to determine whether the growth is malignant or benign.

Soft Tissue Sarcoma Epidemiology Assessment

The epidemiology section offers a comprehensive overview of historical, current, and projected epidemiological trends across the seven major markets (7MM) from 2020 to 2032. It examines various studies and research to identify the factors driving these trends. Additionally, the section includes an in-depth analysis of the diagnosed and prevalent patient populations, future trends, and perspectives from key opinion leaders.

Soft Tissue Sarcoma Epidemiology Insights:

In 2023, the American Cancer Society recorded roughly 13,400 new cases of STS in the United States, with 7,400 cases among males and 6,000 among females. Looking ahead to 2024, projections suggest a slight uptick, with an estimated 13,590 new cases of STS expected nationwide. Of these, approximately 7,700 cases are predicted in males and around 5,890 in females.
According to SEER, the rate of new cases of STS cancer was 3.4 per 100,000 men and womenper year. These rates are age-adjusted and based on 2016–2020 cases.
As per the Cancer Research UK (2021), about 20 out of every 100 soft tissue sarcomas in adults are liposarcomas.

Key Soft Tissue Sarcoma Therapies and Companies

Camsirubicin: Monopar Therapeutics
Lurbinectedin: Jazz Pharmaceuticals
Liposomal Annamycin (L-Annamycin): Moleculin Biotech, Inc.
AL3818: Advenchen Laboratories, LLC
YH001: Tracon Pharmaceuticals Inc.
CFT8634: C4 Therapeutics, Inc.
Olaratumab + Doxorubicin: Eli Lilly and Company
Tazemetostat + Doxorubicin HCl: Epizyme, Inc./Ipsen
Niraparib: GlaxoSmithKline
Seclidemstat: Salarius Pharmaceuticals, LLC
Tinostamustine (EDO-S101): Mundipharma Research Limited
HFB301001: HiFiBiO Therapeutics
Tigilanol Tiglate: QBiotics Group Limited
Pembrolizumab: Merck Sharp & Dohme LLC
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy: Polaris Group
L19TNF and DOXORUBICIN: Philogen S.p.A.
doxorubicin with AGEN1884 and AGEN2034: Agenus Inc
APX005M: Apexigen America, Inc.

Learn How the Soft Tissue Sarcoma Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-market

Soft Tissue Sarcoma Treatment Market

Treatment for soft tissue sarcoma is tailored to the tumor’s type, location, stage, and the patient’s overall health. The primary approaches include surgery, radiation therapy, and chemotherapy, which may be used alone or in combination depending on the individual case.

Surgery is the main treatment for localized soft tissue sarcoma, aiming to remove the tumor along with a margin of healthy tissue to reduce the risk of recurrence. In some cases, reconstructive procedures may be necessary to preserve function and appearance.

Radiation therapy employs high-energy rays to target and destroy cancer cells or shrink tumors, either before surgery or as a standalone treatment for tumors that cannot be surgically removed. It can also be used post-surgery to lower the risk of local recurrence.

Chemotherapy is used for certain types of soft tissue sarcomas with a higher likelihood of spreading to other parts of the body. It involves drugs that kill or slow the growth of cancer cells, administered in cycles to allow the body time to recover between treatments.

Recent advancements in targeted therapies and immunotherapy offer new treatment options, particularly for cases that do not respond well to traditional methods. These innovative approaches specifically target cancer cells or stimulate the body’s immune system to combat the disease.

A multidisciplinary team, including oncologists, surgeons, radiation oncologists, and other specialists, collaborates to develop the most effective treatment plan for each patient. Ongoing follow-ups and monitoring are essential to detect any recurrence or side effects. While treating soft tissue sarcoma presents challenges, continued research and personalized treatment strategies provide hope for improved outcomes and a better quality of life for those affected.

Leading Players in the Soft Tissue Sarcoma Therapeutics Market Include:

Soft Tissue Sarcoma Companies working in the market are Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Soft Tissue Sarcoma Report Covers the In-depth Assessment of the Emerging Soft Tissue Sarcoma Drugs & Key Companies. Download the Soft Tissue Sarcoma Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Key Insights

2. Executive Summary

3. Soft Tissue Sarcoma Competitive Intelligence Analysis

4. Soft Tissue Sarcoma Market Overview at a Glance

5. Soft Tissue Sarcoma Disease Background and Overview

6. Soft Tissue Sarcoma Patient Journey

7. Soft Tissue Sarcoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Soft Tissue Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Soft Tissue Sarcoma Unmet Needs

10. Key Endpoints of Soft Tissue Sarcoma Treatment

11. Soft Tissue Sarcoma Marketed Products

12. Soft Tissue Sarcoma Emerging Drugs and Latest Therapeutic Advances

13. Soft Tissue Sarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Soft Tissue Sarcoma Market Outlook (In US, EU5, and Japan)

16. Soft Tissue Sarcoma Access and Reimbursement Overview

17. KOL Views on the Soft Tissue Sarcoma Market

18. Soft Tissue Sarcoma Market Drivers

19. Soft Tissue Sarcoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Market is expected to grow at a significant CAGR, DelveInsight | Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm

Acute Respiratory Distress Syndrome Market | ARDS Therapies, Clinical trials, ARDS prevalence, ARDS Treatment, ARDS Companies | MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim

“Acute Respiratory Distress Syndrome Market”

As per DelveInsight, the Acute Respiratory Distress Syndrome Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of ARDS in the 7MM.

DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Respiratory Distress Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Acute Respiratory Distress Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Key highlights from the Acute Respiratory Distress Syndrome Market Report:

The acute respiratory distress syndrome market in the 7MM was valued at approximately USD 941 million in 2023 and is projected to grow by 2034. Among the 7MM, the U.S. had the largest market share in 2023, accounting for around USD 666.9 million. This figure is expected to rise further by 2034 due to increasing rates of chronic health conditions and the emergence of new infectious diseases, including novel viral strains.
Several factors contribute to the rising incidence of ARDS. Environmental pollutants, such as air pollution and toxins, exacerbate respiratory issues. Additionally, chronic conditions like diabetes, heart disease, and obesity, especially when poorly managed, elevate the risk of developing ARDS.
The ARDS market is anticipated to experience steady growth from 2024 to 2034. This growth is driven by an aging population that is more susceptible to long-term illnesses, weakened immune systems, and an increased prevalence of viral and bacterial infections, including pneumonia, influenza, sepsis, and emerging coronavirus strains.
Current treatment strategies for ARDS include supportive care, mechanical ventilation, oxygen therapy, sedation, corticosteroids, ACE inhibitors, ARBs, neuromuscular blockers, inhaled vasodilators, and, in some cases, extracorporeal membrane oxygenation (ECMO). Supportive measures such as prone positioning, fluid management, and conservative fluid strategies are also used to optimize patient outcomes.
Key Acute Respiratory Distress Syndrome companies are MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.
Expected launch of emerging therapies, such as Traumakine (Faron Pharmaceuticals) BIO-11006 (BioMarck Pharmaceuticals), MultiStem (Athersys), Solnatide (Apeptico Forschung und Entwicklung GmbH), PB1046 (PhaseBio Pharmaceuticals), and others are expected to create a positive impact on the ARDS treatment scenario and ARDS market outlook in the upcoming years.
In June 24, 2024, InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three investigational therapies to be assessed in a Phase 2 clinical platform study exploring potential new options for the treatment of acute respiratory distress syndrome (ARDS).
In Dec 2023, the PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS). BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

Read detailed insights on ARDS market outlook 2034 @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

Acute Respiratory Distress Syndrome Overview

Acute respiratory distress syndrome (ARDS) is a rapidly progressive condition that primarily affects critically ill patients. It is marked by the accumulation of fluid in the lungs, which severely impairs breathing and results in low blood oxygen levels. ARDS often arises as a complication of another serious illness or major injury, leading to fluid buildup in the lung’s tiny air sacs and a breakdown of surfactant.

The causes of ARDS are categorized into two main types: direct and indirect lung injuries. Direct lung injuries include conditions such as pneumonia, aspiration, and trauma. Indirect lung injuries involve systemic issues such as pancreatitis, severe infections (sepsis), blood transfusion reactions, burns, and adverse drug reactions. The initial symptoms of ARDS typically include shortness of breath, cough, and fever. Other signs may involve low blood oxygen levels, rapid breathing, and abnormal lung sounds such as clicking, bubbling, or rattling.

Early detection of acute respiratory distress syndrome (ARDS) is crucial for promptly initiating lung-protective ventilation strategies. Despite efforts to refine disease definitions, ARDS is often under-recognized by clinicians, with diagnoses frequently delayed. Reports suggest that up to 40% of ARDS cases are under-diagnosed, with diagnostic rates improving as the disease severity increases. ARDS diagnosis relies on several clinical criteria, none of which are particularly precise. For instance, the Berlin definition has a specificity of only 63% for detecting diffuse alveolar damage (DAD) at autopsy. Currently, no specific biomarker exists for ARDS diagnosis, making this a significant focus of ongoing research.

Chest X-rays (CXR) have relatively low sensitivity and specificity (around 70%) compared to CT scans for diagnosing ARDS. CXR is more effective in identifying diffuse or patchy infiltrates than focal ones. The use of CT scans and other imaging techniques has become increasingly important in diagnosing and managing ARDS. Additionally, lung ultrasound is gaining recognition as a useful bedside tool for facilitating ARDS diagnosis.

Acute Respiratory Distress Syndrome Treatment Market

The treatment of acute respiratory distress syndrome (ARDS) primarily involves supportive care. This includes mechanical ventilation, prevention of stress ulcers and venous thromboembolism, and nutritional support. Effective supportive care for ARDS patients, as with other ICU patients, encompasses early enteral feeding, good glycemic control, prevention of deep venous thrombosis, and prophylaxis against stress ulcers. It is also crucial to identify and treat any underlying infections with antibiotics tailored to culture sensitivities; if cultures are unavailable, antibiotics should target common pathogens relevant to the infection site.

Additional treatments for ARDS patients typically involve supplemental oxygen, prone positioning, the use of neuromuscular blockers (paralytics), fluid management, and positive end-expiratory pressure (PEEP) to help expel fluid from the air sacs. These supportive measures are combined with ongoing treatment of the primary illness or injury. Given that ARDS patients are more susceptible to lung infections, such as bacterial pneumonia, antibiotics are administered to manage these infections. Supportive care may also include intravenous fluids or nutrition as needed.

Acute Respiratory Distress Syndrome Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.

Acute Respiratory Distress Syndrome Epidemiology Insights:

In 2023, DelveInsight estimated approximately 862,000 new cases of acute respiratory distress syndrome (ARDS) across the 7MM. This number is expected to rise over the forecast period from 2024 to 2034, largely due to environmental factors such as air pollution and toxin exposure, which exacerbate respiratory diseases.
In the U.S., there were about 545,000 new ARDS cases in 2023. This figure is anticipated to grow by 2034 due to the increasing prevalence of chronic conditions like diabetes, heart disease, and obesity.
Among the EU4 and the UK, Germany had the highest incidence of ARDS with approximately 157,000 cases in 2023, followed by Italy with around 45,000 cases. Spain had the lowest incidence, with about 21,000 cases.
In 2023, the EU4 and the UK reported approximately 44,000 cases of mild ARDS, 132,000 cases of moderate ARDS, and 122,000 cases of severe ARDS.
In Japan, there were about 19,000 new ARDS cases in 2023. The primary risk factors included pneumonia (34%), sepsis (29%), trauma (7%), aspiration (10%), pancreatitis (2%), other causes (16%), and unknown factors (2%).

Acute Respiratory Distress Syndrome Emerging Drugs

Edesa Biotech/Light Chain Biosciences: EB05 (paridiprubart)
Boehringer Ingelheim/ Genentech: Alteplase (Actilyse)
BioMarck Pharmaceuticals: BIO-11006
Direct Biologics: ExoFlo (DB-001)

Learn How the Acute Respiratory Distress Syndrome Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market

Acute Respiratory Distress Syndrome Market/ ARDS Market Outlook, ARDS Treatment Market

Despite significant research efforts, treatment options for acute respiratory distress syndrome (ARDS) are still limited, mainly focusing on supportive care and mechanical ventilation. Current management approaches involve supplemental oxygen, prone positioning, the use of paralytics, fluid management, and positive end-expiratory pressure (PEEP) to help remove fluid from the lungs. Patients often need antibiotics for infections such as bacterial pneumonia and may also require intravenous fluids or nutritional support.

ARDS involves alveolar flooding and pulmonary edema. Studies suggest that β2 agonists might aid in alleviating pulmonary edema by improving sodium transport in alveolar cells. Additionally, accelerating the repair of alveolar epithelial cells is important, with keratinocyte growth factor (KGF) showing potential benefits in both experimental and clinical studies.

Recent advancements include the FDA’s emergency use authorization of Actemra/RoActemra (tocilizumab) for patients requiring supplemental oxygen or mechanical ventilation, and the approval of Pluristem Therapeutics’ Expanded Access Program for PLX-PAD cells in ARDS related to COVID-19. However, these treatments primarily target inflammation rather than directly improving lung function.

Given the substantial unmet need for effective ARDS therapies, several new treatments are being developed and are expected to significantly impact the market. These emerging therapies, such as EB05, BIO-11006, MultiStem, Alteplase, Lucinactant, and DB-001, are projected to be available between 2024 and 2032 and could significantly alter the ARDS treatment landscape.

Leading Players in the Acute Respiratory Distress Syndrome Therapeutics Market Include:

ARDS Companies working in the market are MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, APEPTICO Forschung und Entwicklung GmbH, Staidson (Beijing) Biopharmaceuticals, Veru, Mesoblast Limited, Avalo Therapeutics, Pluristem Therapeutics, ILTOO Pharma, and others.

Table of Contents

1. Key Insights

2. Executive Summary

3. Acute Respiratory Distress Syndrome Competitive Intelligence Analysis

4. Acute Respiratory Distress Syndrome Market Overview at a Glance

5. Acute Respiratory Distress Syndrome Disease Background and Overview

6. ARDS Patient Journey

7. ARDS Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Acute Respiratory Distress Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. ARDS Unmet Needs

10. Key Endpoints of Acute Respiratory Distress Syndrome Treatment

11. Acute Respiratory Distress Syndrome Marketed Products

12. Acute Respiratory Distress Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Acute Respiratory Distress Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. ARDS Market Outlook (In US, EU5, and Japan)

16. ARDS Access and Reimbursement Overview

17. KOL Views on the Acute Respiratory Distress Syndrome Market

18. ARDS Market Drivers

19. ARDS Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Respiratory Distress Syndrome Market | ARDS Therapies, Clinical trials, ARDS prevalence, ARDS Treatment, ARDS Companies | MediciNova, Edesa Biotech, Light Chain Biosciences, Boehringer Ingelheim

Greenr Launches AI-Powered Waste Bin with Potential to Transform the Waste Management Industry and Drive Better Sustainability Outcomes

Greenr’s EcoSortAI Waste Containers Automatically Separate Waste and Identify Garbage Using AI and an Infrared Camera—Radically Changing the Waste Management Value Chain by Decontaminating and Sorting Waste Ahead of Recycling

VALENCIA, SPAIN – Sep 5, 2024 – Greenr, the world’s proven sustainability company, today announced the introduction of EcoSortAI, a revolutionary waste bin that easily and automatically separates waste using AI and infrared technology. EcoSortAI addresses many of today’s most urgent and difficult waste management challenges. It radically changes the waste management value chain by decontaminating and sorting waste ahead of recycling

EcoSortAI identifies the type of waste that is thrown away and separates it by category. The bin’s camera scans a container and monitors whether the garbage is a plastic bottle or an apple. It stores and sorts waste.

By automatically separating waste, EcoSortAI has the potential to transform the entire waste management industry. With EcoSortAI, recycling and sorting become easier, resulting in less contaminated waste, higher calorific value from waste, greater return from recycling, and a closed circular model. Landfilling will drop dramatically. This opens up opportunities for better investment and development on these lands, along with job creation. Additionally, the bin makes it unnecessary for people to spend on waste awareness and separation. Businesses will no longer have to spend money educating their employees on where to throw away waste and recycling.

The current state of waste management reveals the significance of EcoSortAI’s innovations. Right now, half of the food waste that people throw out could be composted. As much as 80% of trash could be recycled.

“The problem with waste and recycling is that sorting is not efficient,” said Emad, Founder of Greenr, which is owned by SeedersCapital. “People do not want the hassle of garbage bags, bad smells, continual odor, and rodents. Companies with inefficient waste management are burdened with significant operational costs. Informal collection by people looking through garbage hampers contracted garbage removal. These are the problems we are solving with EcoSortAI.”

Many industries are searching for better ways to manage waste and want to address ongoing and efficient sorting, to offset high operational costs, and low recycling rates. Those who can begin to benefit the most from sorting are facility decision makers, sustainability managers, real estate developers, airports, hospitals, train stations, municipalities, universities, and hotels. The spokesperson added, “If waste is sorted, recycling can be more efficient, and the separated garbage can be sold to companies looking for consistent waste products to repurpose or sell through the value chain.”

EcoSort is establishing a sustainable waste management structure, from sorting garbage to completely moving through the value chain, offering cost savings, improved recycling, and environmental benefits.

EcoSort AI can make a significant difference in waste management practices.

This is the first step in a process that supports sorting waste and organizing garbage through a continual chain, which will culminate in value and profits, all from original garbage. Users can sell decontaminated waste to the end users or even recycle on site.

For more information, visit www.greenr.life

Media Contact
Company Name: Greenr
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: www.greenr.life

SaNDAI Cares Inc. Partners with Foundation for a Healthier Senegal to Empower Communities Through AI Literacy

Hands-on program develops future workforce by enabling participants to gain key expertise and excel in a data-driven world

WASHINGTON, D.C. – SaNDAI Cares Inc., the not-for-profit arm of SaNDAI Global (SaNDAI), a leading data and business intelligence company, is excited to announce its partnership with the Foundation for a Healthier Senegal (FOHSEN) to upskill FOHSEN staff in critical areas such as data literacy, AI ethics, responsible use of AI, AI fundamentals, and generative AI applications. This partnership is part of SaNDAI’s AI Literacy Leaders Program: Africa, designed to empower and educate key stakeholders across the continent.

The program will run for 52 weeks and will equip participants with certificates in data and AI-related fields, validating their expertise and preparing them to leverage emerging technologies. This initiative reflects SaNDAI’s mission to promote data-driven decision-making and foster innovation within underrepresented and marginalized communities. SaNDAI annually dedicates thousands of hours to analytics training, supporting growth, innovation, and new knowledge across the globe.

“AI Literacy Leaders Program: Africa aims to empower over 900 youth, young adults, educators, and community leaders across Africa with essential digital, data, and AI literacy skills,” said Jeremy Williams Sr., Chief Executive Officer of SaNDAI. “These skills are crucial, especially for African rural students, as they open doors to new opportunities, enable community transformation, and contribute significantly to the continent’s prosperity and sustainability.”

Through this partnership, FOHSEN will enhance its capabilities in three critical areas: maternal and child health, expanding health infrastructure, and increasing the use of telemedicine. “The skills we will acquire through our collaboration with SaNDAI will revolutionize how we manage and interpret data, ultimately improving our ability to deliver essential services in Senegal,” said Talla Cisse, Executive Director of FOHSEN. FOHSEN is committed to improving health outcomes for rural and underserved women across Senegal by increasing access to reproductive, maternal, and child health services through community-driven initiatives.

“Our work with SaNDAI and other partners, including the Ministry of Health and Senegalese communities, focuses on addressing persistent health and equity gaps,” added Richard Szeto, Finance Manager at FOHSEN. “This partnership is vital as we strive to expand access to quality nutrition, family planning services, and overall health infrastructure, making a meaningful impact on the lives of those we serve.”

The collaboration between SaNDAI and FOHSEN marks a significant step toward empowering communities in Senegal and beyond. It showcases the transformative power of data literacy and AI education in driving social change and improving health outcomes.

About SaNDAI Cares Inc.:

SaNDAI Cares Inc. is the philanthropic division of SaNDAI Global, dedicated to empowering marginalized communities through data-driven education and innovation. Focusing on providing accessible training in data literacy and AI, SaNDAI Cares aims to bridge the digital divide and create sustainable, positive change worldwide.

SaNDAI’s program partners include Microsoft, DataCamp, Synthesia, Gamma, Alexandria City High School, GiSTEM, and Soundraw.

About Foundation for a Healthier Senegal (FOHSEN):

FOHSEN is a nonprofit organization focused on improving health outcomes for rural and underserved populations in Senegal. By expanding access to reproductive, maternal, and child health services, FOHSEN aims to reduce health disparities and promote wellness nationwide.

For more information, visit https://sandaicares.org/ and https://fohsen.org/.

Media Contact:

Jeremy Williams, Sr.
CEO
info@sandaicares.org

Media Contact
Company Name: SaNDAI Cares Inc
Contact Person: Jeremy Williams, Sr.
Email: Send Email
Country: United States
Website: https://sandaicares.org/

SMX Technology Can Serve the Urgent Need for Accountability in Sustainable Packaging ($SMX)

As the world edges closer to the critical deadlines set for sustainable packaging, major brand owners like PepsiCo (NYSE: PEP), Unilever (NYSE: UL), and Colgate-Palmolive (NYSE: CL) have recently announced that they will fail to reach their sustainable packaging objectives. This revelation, while disappointing, is not entirely surprising. In 2021, John Blake, a senior director analyst at Gartner, predicted this trend, highlighting the numerous challenges companies would face in pursuing ambitious environmental goals. Now, as 2024 draws to a close, it’s clear that these challenges have become nearly impossible for many organizations, not necessarily because of intent but rather because of the lack of technological support needed to accomplish the transformational mission.

That’s no longer the case- or an excuse. SMX (Security Matters) (NASDAQ: SMX) offers a solution to quiet the industry’s growing woes. What does this mean for the future of sustainable manufacturing and packaging? A lot. And it could be one of those generational win-win propositions that both the world and investors can embrace. In no uncertain terms, SMX is offering the right things at the right time to enable sustainable manufacturing and packaging, a movement that began gaining traction six to seven years ago in direct response to increasing public awareness of global plastic pollution and the urgent need to combat climate change. In its early stages, the movement was marked by the development of bio-based plastics and programs to capture Life Cycle Assessments (LCAs) of packaging to increase recycling. However, the global financial crisis of 2007-2009 dealt a severe blow to these initiatives, as cost-cutting measures led to the increased use of multi-layer rigid plastics and high-barrier thin films—materials that, while economically advantageous, are notoriously difficult to recycle.

Thankfully, although slowed, the initiative wasn’t stopped. From 2018 to 2020, the industry witnessed unprecedented commitments to reduce or eliminate plastic usage, increase recycling rates, and curb reliance on single-use packaging. Many of these commitments were set with a 2025 target date. However, as Blake and his team at Gartner predicted, despite the great intentions, the global reliance on plastics and the lack of sufficient recycling and reuse infrastructure would make it nearly impossible for most organizations to meet these ambitious goals.

The Harsh Reality of Complex Packaging

That’s not entirely the companies’ fault. The complexity of sustainable packaging is often underestimated by those outside of the packaging research and development (R&D) and converting industries. Plastics, for example, have been highly engineered over several decades to provide lightweight, safe, economical, and convenient benefits. However, these materials were never designed with easy or economical reuse or recycling in mind. Now, as companies attempt to unwind decades of innovation within a few short years, they have encountered significant technical and economic challenges.

One of the most significant issues is the shortage of high-quality, food-grade recycled plastics. This scarcity has created economic, quality, and regulatory hurdles that many companies struggle to overcome. Additionally, the supply chains and reverse logistics necessary for reusable packaging are still underdeveloped, requiring substantial investment to achieve the scale needed to make a meaningful impact.

As the year approaches 2025, many organizations are being forced to reassess their commitment to sustainable packaging. The original goals—such as making 100% of packaging reusable, recyclable, or plastic-free—were often adopted without thorough vetting by R&D, supply chain, quality, procurement, and manufacturing teams. While popular with consumers and beneficial to brand perception, these pledges are proving to be technically and economically unfeasible in the short term.

Recycling: Ambition vs. Reality

In fact, the gap between the ambitious vision of sustainable packaging and the reality of its implementation has become increasingly evident. For packaging materials to be genuinely recyclable, they must be recycled at scale, which requires greater industry collaboration and government intervention. Moreover, the complex nature of packaging—where product safety, transport efficiency, and economics must all be considered—means that simply changing the packaging is not a viable solution.

The European Commission’s recent announcement of an infringement procedure against all 27 EU Member States for failing to meet legally binding collection and recycling targets underscores the global scale of the problem. The Packaging and Packaging Waste Directive, which expected Member States to recycle 55-80% of packaging waste by the end of 2008, has been widely missed. Even today, countries across Europe are laboring to meet these targets, with the vast majority falling short of the Waste Framework Directive’s 2020 goals.

The failure of EU Member States to meet their recycling targets is a stark reminder that the world needs innovative solutions to tackle the waste crisis. This is where SMX (Security Matters) marking technology could play a crucial role.

SMX Technology Is A Game-Changer for Sustainable Packaging

SMX technology is a cutting-edge solution developed by Security Matters that offers a promising approach to overcoming the challenges faced by the packaging and manufacturing industries. Unlike any other known tracking technology, SMX’s invisible marker system can be permanently embedded into virtually any liquid or solid material, allowing for accurate tracking and verification throughout a product’s entire lifecycle. This technology has the potential to revolutionize recycling by providing greater transparency and traceability in the waste management process.

For instance, SMX technology, which is blockchain-inclusive, could help identify and sort different types of plastics more efficiently, ensuring that high-quality, food-grade recycled materials are separated and reused effectively. This would address the current shortage and improve the overall quality of recycled products. Moreover, SMX technology could facilitate better monitoring of packaging throughout its lifecycle, enabling companies to ensure that their materials are being reused or recycled as intended.

In addition to its recycling benefits, SMX technology could also support companies in meeting their regulatory obligations. By providing a reliable method for tracking and verifying packaging materials, SMX could help organizations demonstrate compliance with increasingly stringent packaging laws and regulations. This would reduce the risk of legal repercussions and enhance the brand’s reputation by showcasing and following through with its commitment to sustainability.

Collaboration Aligned With Innovation

Indeed, the packaging industry’s ambitious targets should be applauded for driving progress. Still, it’s clear that a new approach is needed to overcome the challenges that lie ahead. Organizations must take a pragmatic approach to sustainable packaging, leveraging the lessons learned by early adopters and understanding the limitations and opportunities specific to their regions. That’s a big step forward, but only one of the ones that’s needed.

Greater collaboration between industry stakeholders and government bodies is also essential to developing the infrastructure needed to support sustainable packaging at scale. Investment in innovation, such as SMX technology, will be crucial to overcoming the technical and economic barriers that have hindered progress thus far. As we look to the future, what has been exposed as being undeniably vital is that companies maintain transparent communication with stakeholders, including consumers, about the challenges they face in meeting their sustainable packaging goals. By acknowledging issue complexities and investing in innovative solutions, the industry can chart a new course toward a more sustainable future.

This time, by utilizing available technologies like the one SMX provides, major companies and entire nations have a better chance than ever to meet their recycling mandates to address the global waste crisis. Technologies like SMX offer more than a glimmer of hope; they provide the tools needed to improve recycling rates and ensure that packaging materials are managed responsibly throughout their lifecycle. And with SMX technology integrating seamlessly into that intention, that goal can be accelerated, which is more than helpful to companies, it helps protect the planet for future generations.

Disclaimers and Disclosures: This Disclaimer and Disclosure statement is a permanent part of this content. Any reproduction of this content in part or whole that does not include the Disclaimer and Disclosure statement is unauthorized and strictly prohibited. Hawk Point Media Group, Llc. (HPM) is responsible for the production and distribution of this content. Hawk Point Media Group, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by Hawk Point Media Group, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors do NOT buy and sell securities before and after any particular article, report and publication. HPM holds ZERO shares of SMX (Security Matters) stock. HPM has not been compensated to produce and syndicate this content. In no event shall Hawk Point Media Group, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by Hawk Point Media Group, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Contributors reserve the right, but are not obligated to, submit articles for fact-checking prior to publication. Contributors are under no obligation to accept revisions when not factually supported.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SMX Technology Can Serve the Urgent Need for Accountability in Sustainable Packaging ($SMX)

Proven Leadership Team With A History Of Unlocking Shareholder Value Could Drive Railtown AI Higher

Back in July, CrowdStrike released a configuration update for their Falcon sensor, which inadvertently caused a system crash on Windows systems across the world. This issue was triggered by a logic error in the update that affected systems running Falcon Sensor for Windows, which resulted in downloading the faulty configuration during a specific timeframe.

The fallout was immediate and widespread, impacting banks, airlines, and various other critical sectors globally. Systems crashed, operations halted, and organizations were left scrambling to restore functionality. This disruption also opened the door for cybercriminals to exploit the situation, as they began distributing phishing emails and malicious files masquerading as solutions to the issue.

In what’s been described as the largest IT outage in history that cost Fortune 500 companies alone more than $5 billion in direct losses, according to one insurer’s analysis of the incident, one under-the-radar company seems well positioned to prevent the possibility of such events in the future, thus attracting significant investor interest.

Railtown AI Technologies (CSE:RAIL) (OTCQB:RLAIF) is a promising player in the AI sector, offering innovative solutions that streamline software development. As a Microsoft Partner, Railtown AI has developed a cloud-based Application General Intelligence (AGI) platform designed to support software developers and Agile teams.

The company’s main objective is to leverage artificial intelligence to catch errors before they reach production, and here’s how it could have mitigated the issues faced by CrowdStrike:

Automated Code Analysis: Railtown AI employs advanced machine learning algorithms to perform continuous and automated analysis of code. This enables the company to detect anomalies and potential errors that might be missed during manual reviews through alerts.
Predictive Insights: The AI-driven platform not only identifies existing errors but also predicts areas of code that are more likely to contain future issues. This predictive capability helps developers focus their attention where it’s needed most.
Integration with Development Tools: Railtown AI seamlessly integrates with popular development environments and CI/CD pipelines, ensuring that error detection is an integral part of the development process, not an afterthought.
Enhanced Security: By identifying and addressing vulnerabilities early, Railtown AI enhances the security posture of software, reducing the risk of exploitation and ensuring user trust and safety.

In addition to that, Railtown also helps assist developers to save time on repetitive tasks, improve productivity, reduce costs, and accelerate developer velocity. This platform is readily accessible via Microsoft’s Azure Marketplace, making it easily available to a broad range of businesses.

Although there’s been a lot of hype surrounding how AI companies could disrupt the future of coding and programming, investors need to be aware that not all AI companies will turn out to be the next unicorn. Picking out a winner in the sector is particularly challenging due to the rapid pace of advancement as well as the increasing complexity of the capabilities of these systems, making it hard for non-tech people to comprehend.

However, one strategy that has worked for savvy investors across different sectors of the market has been looking at the founders or leadership track record in creating shareholder value. A closer look at Railtown reveals that it has a proven leadership team with a history of driving growth for shareholders, which should bode well for the company’s stock.

For starters, Railtown co-founder and CTO Marwan Haddad has over 25 years of software development experience in addition to 10 years of experience leading and building high-performance engineering and product development teams. He was the Chief Technology Officer and Vice President of Engineering for RESAAS, a global award-winning proptech cloud platform.

He has also led the development efforts/teams and launched several platforms for Fortune 500 companies, including Microsoft and Starbucks.

CEO Cory Brandolini has over 30 years of experience as a founder, partner, angel investor, financier, and advisor to disruptive, high-growth software companies within the technology industry. His wealth of capital markets experience includes helping raise well over $150 million for private and public technology companies. Cory Brandolini has over 30 years of experience as a founder, partner, angel investor, financier, and advisor to disruptive, high-growth software companies within the technology industry.

His wealth of Capital Markets experience includes helping raise well over $150 million for private and public technology companies.

Co-founder Dr. Elliot Holtham has a wide range of experience in natural sciences, engineering, and technology. While he has a passion for developing innovative technology, his strong work ethic and competitive drive have also enabled him to advise and lead groups to success. Previously, he was co-founder, CEO, and COO of Xtract AI, a machine learning company that was later acquired by Patriot One Technologies (TSX:XTRA) for about $6 million.

Last but not least is Kevin O’Neil, who has over 35 years of experience in technology investing, advisory, and leadership. He was formerly the CEO of Xtract AI and also an investment banker at Merrill Lynch.

More importantly, Railtown AI’s proprietary platform is entirely owned and developed in-house, ensuring that the company has complete control over its technology. The platform offers dual deployment options, catering to organizations with different needs by offering both cloud-based and on-premise solutions. This flexibility, combined with the platform’s ability to process data quickly and learn over time, allows businesses to make real-time decisions and continuously improve their software development processes.

Additionally, Railtown AI‘s focus on compliance with industry standards such as SOC 2, GDPR, and ISO 27001 is a significant advantage, as these compliance achievements build customer trust by ensuring that the platform handles data responsibly and securely.

Railtown AI has achieved several milestones, reaffirming that its business model has been validated by the market. These include the company’s recently announced debt-free status and strengthening of its capital base through private placements. Clearly, those achievements, combined with strategic partnerships with leading institutions like the Mila Quebec AI Institute and Amii Alberta Machine Learning Institute, set the stage for future growth.

Going forward, we believe that Railtown AI is poised to capitalize on its strong leadership team to unlock shareholder value as the company positions itself to rapidly scale user acquisition and commercialize new features on the platform.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Proven Leadership Team With A History Of Unlocking Shareholder Value Could Drive Railtown AI Higher

How Iveda Solutions (NASDAQ: IVDA) is Redefining Industry Norms with Advanced AI Applications

The artificial intelligence (AI) sector is experiencing unprecedented growth, driven by advancements that are transforming various industries. The global AI market is projected to reach $826 billion by 2030, propelled by a compound annual growth rate of 28.46% from 2024 to 2030. This rapid expansion reflects a broader technological shift, with companies increasingly integrating AI to enhance performance and uncover new opportunities.

Amid this dynamic landscape, Iveda Solutions, Inc. (NASDAQ: IVDA) is making notable strides. Iveda Solutions is carving a prominent niche in the realm of cloud-based AI and video surveillance technologies. The company’s innovative approach integrates smart devices with AI to offer transformative solutions across public safety, environmental preservation, elderly care, and energy efficiency.

Let’s take a closer look at the company.

Recent Developments and Innovations

One of Iveda Solutions, Inc.‘s latest advancements is the vumastAR AI software, a cutting-edge tool designed to detect oil spills. This new initiative targets major oil companies in Australia and the US, addressing a critical need in the oil and gas industry. VumastAR, pronounced “view master,” is an AI vision software that interfaces with a variety of smart devices, such as IP cameras and AR glasses, to provide real-time insights and automated alerts. This system is poised to revolutionize the $175.79 billion oil spill management market by reducing the labor-intensive and costly process of manual spill detection. David Ly, CEO and Founder of IVDA, highlighted the significance of this technology: “We’ve seen a significant increase in interest from the oil and gas industry for AI solutions that can enhance safety and environmental protections. Our focus remains on delivering cutting-edge technology that aligns with ESG principles, ensuring that our solutions not only meet industry needs but also contribute to broader sustainability goals.”

In addition to vumastAR, the company has filed a patent for its LevelNOW IoT sensor, a sophisticated liquid storage management solution. LevelNOW provides real-time monitoring of liquid storage, addressing issues like leaks, evaporation, and theft. This innovative sensor has already proven its worth in optimizing operations for major oil companies in Australia. “This innovation comes from being in the field with our customers and truly listening to their needs and desires,” said Ly. “By enhancing our LevelNOW solution through this new patent, Iveda is underscoring its commitment to industry-specific innovation that simplifies everyday workflows.”

Iveda’s dedication to industry-specific solutions is further exemplified by its integration of IvedaCare and IvedaAI at Waymark Gardens, a senior living facility in Glendale, AZ. This integration marks a significant step in enhancing remote patient monitoring. IvedaCare utilizes camera-less sensors for private monitoring, while IvedaAI provides real-time video analysis in public areas. This combination supports IVDA’s subcontract under a substantial $1.032 billion Veterans Affairs contract, demonstrating the company’s capability to deliver tailored AI solutions in healthcare. Ly commented on this development: “Facilities using IvedaCare for remote patient monitoring are now discovering the enhanced capabilities of IvedaAI. Waymark Gardens’ adoption of IvedaAI is a showcase and testament to the growing value of these solutions.”

Financial Performance and Market Outlook

Iveda Solutions, Inc.’s financial performance in the second quarter of 2024 shows a decline in revenue by 36% year-over-year, amounting to $1.53 million. However, the company managed to beat earnings per share (EPS) expectations, with a loss of $0.03 per share, which was an improvement from $0.048 per share in the same quarter last year. Looking ahead, Iveda Solutions (NASDAQ: IVDA) forecasts a robust average annual revenue growth of 122% over the next two years, significantly surpassing the 12% growth anticipated for the broader software industry.

Strategic Position and Future Prospects

IVDA’s strategic initiatives, including its advancements in AI applications for diverse industries, position it as a company with considerable growth potential. Its recent launch of the IvedaAI Forensics Desk, which provides law enforcement in the Philippines with advanced video intelligence tools, further highlights the company’s expansive reach and innovative spirit. As Timmy Evangelista, Chief Technology Officer of Iveda Solutions, Inc. (NASDAQ: IVDA) Philippines, noted, “The IvedaAI Forensics Desk is uniquely valuable for law enforcement and security officials operating in high-traffic, tourist locations.”

In summary, Iveda Solutions, Inc. (NASDAQ: IVDA) continues to make significant strides in cloud-based AI and video surveillance, with promising innovations and strategic expansions across various sectors. As the company pushes the boundaries of technology and addresses critical industry needs, it stands as a key player in the evolving landscape of digital transformation.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How Iveda Solutions (NASDAQ: IVDA) is Redefining Industry Norms with Advanced AI Applications

Nuance Energy Announces Comprehensive Solutions for Solar Racking Systems

Nuance Energy, a leading provider of innovative solar racking solutions, is proud to announce its latest offerings designed to meet the growing demands of the renewable energy industry. With a solid commitment to advancing solar technology, Nuance Energy continues to provide robust and cost-effective solutions for various solar installations, including solar racking for ground mount systems.

Sep 5, 2024 – As the solar industry continues to expand, the need for reliable and efficient racking systems has never been greater. Nuance Energy’s latest product lineup includes advanced solutions such as fix tilt solar racking, canopy solar racking, carport solar racking, and distributed solar racking, all designed to optimize solar panel installations across various environments.

Innovations in Solar Racking for Ground Mount Systems

Nuance Energy’s solar racking for ground mount systems is engineered to provide unparalleled stability and ease of installation. These systems are ideal for large-scale solar projects that require a sturdy foundation to support solar panels in diverse terrains. The company’s ground mount solutions are designed to withstand harsh environmental conditions, ensuring long-term durability and performance.

Fix Tilt Solar Racking: Efficiency and Reliability

The fix tilt solar racking systems are tailored for projects requiring a fixed tilt angle. These systems offer a cost-effective solution that maximizes energy production by maintaining an optimal tilt angle throughout the year. The fixed-tilt design reduces the complexity of installation and maintenance, making it a preferred choice for many solar developers.

Canopy and Carport Solar Racking: Versatile Solutions for Urban Spaces

Nuance Energy’scanopy and carport solar racking solutions are designed to bring solar energy to urban environments where space is often limited. The canopy systems provide shade while generating clean energy in parking lots, walkways, and other open areas. The carport systems, on the other hand, are ideal for integrating solar panels into parking structures, offering both vehicle protection and a source of renewable energy.

Distributed Solar Racking: Adapting to Diverse Installations

Nuance Energy’s distributed solar racking systems are designed to meet the unique needs of decentralized solar installations. These highly adaptable systems make them suitable for various applications, from residential rooftops to remote off-grid locations. Distributed solar racking provides flexibility in system design, allowing for the efficient deployment of solar panels in areas with limited space or challenging layouts.

About Nuance Energy

Nuance Energy is dedicated to providing innovative and sustainable solar racking solutions that support the global transition to renewable energy. With a focus on quality, reliability, and customer satisfaction, the company continues to lead the industry in developing products that meet the evolving needs of solar energy providers. Nuance Energy’s commitment to excellence is reflected in its comprehensive product offerings, which are designed to enhance the efficiency and longevity of solar installations worldwide.

For more information about Nuance Energy and its range of solar racking solutions, please visit Nuance Energy.

Media Contact
Company Name: Nuance Energy
Contact Person: Brian C. Boguess
Email: Send Email
Phone: (877) 537-2221
Country: United States
Website: https://nuanceenergy.com/

Locksmith 4 You Explains How to Avoid Scams During a House Lockout

Locksmith 4 You is a leading locksmith service company. In a recent update, the company explained how to avoid scams during a house lockout.

St. Louis, MO – In a website post, Locksmith 4 You explained how to avoid scams during a house lockout.

The locksmith St. Louis it is essential to be cautious of locksmiths who provide an unusually low estimate over the phone. Scammers often lure individuals with the promise of cheap services, only to hike up the price once on-site, claiming the job is more complex than anticipated. To avoid this trap, insist on a written estimate before any work begins, ensuring the price won’t unexpectedly skyrocket.

The experts asserted that another way to steer clear of lockout scams is to pay close attention to the locksmith’s credentials. A trustworthy locksmith in St. Louis will arrive in a marked vehicle, carry identification, and be willing to provide proof of their insurance and licensing if applicable. If a locksmith arrives in an unmarked car, lacks identification, or seems hesitant to show credentials, it is wise to question their legitimacy.

The professionals mentioned that it is crucial to be wary of locksmiths who insist on drilling or replacing the lock. In most cases, a skilled locksmith Near St. Louis can unlock a door without causing damage. Scammers may suggest unnecessary drilling as a way to charge for expensive replacement locks. It is important to understand that drilling is typically a last resort for situations involving high-security locks or unusual circumstances.

About Locksmith 4 You

Locksmith 4 You is a premier locksmith service company. The team is trained to work with the latest technologies, ensuring that every job is completed to the highest standard. Transparency and integrity are at the core of their operations, ensuring that every service is delivered with honesty and professionalism. Dedicated to providing comprehensive security solutions, Locksmith 4 You is available around the clock to assist with any locksmith needs.

Media Contact
Company Name: Locksmith 4 You
Contact Person: Nick
Email: Send Email
Phone: (314) 207-3993
Address:Delmar Blvd Apt
City: St. Louis
State: MO
Country: United States
Website: https://www.locksmith4you.org/

Mokolo Law Firm, PLLC Expands Services to Meet the Growing Legal Needs of Houston Community

Mokolo Law Firm, PLLC is a distinguished Houston-based legal practice specializing in family law, immigration, and personal injury cases. With a commitment to personalized client care and a thorough understanding of complex legal matters, the firm delivers tailored legal solutions to meet the unique needs of its diverse clientele.

Houston, TX – Mokolo Law Firm, PLLC, has a strong commitment to providing exceptional legal representation, the firm continues to specialize in family law, immigration law, and personal injury cases, ensuring that residents of Houston have access to top-tier legal support.

Mokolo Law Firm, PLLC is proud to offer its clients comprehensive legal solutions tailored to their unique circumstances. As a trusted Family Attorney in Houston, the firm has extensive experience handling a wide range of family law matters, including divorce, child custody, and spousal support. The team at Mokolo Law Firm is dedicated to helping clients navigate the complexities of family law with compassion and expertise, ensuring that each case is handled with the utmost care.

In addition to family law, Mokolo Law Firm, PLLC is recognized as a leading Immigration Attorney in Houston. The firm assists clients with various immigration issues, including visa applications, green cards, and citizenship. By staying up-to-date with the latest immigration laws and policies, Mokolo Law Firm provides clients with reliable legal guidance, helping them achieve their immigration goals.

For those facing child custody disputes, Mokolo Law Firm, PLLC offers the services of an experienced Child Custody Attorney in Houston. The firm is dedicated to advocating for the best interests of the child while ensuring that clients receive fair and just outcomes in their custody cases.

About Mokolo Law Firm, PLLC

Mokolo Law Firm, PLLC is a Houston-based legal firm specializing in family law, immigration, and personal injury. Known for its client-focused approach, the firm offers expert legal guidance and personalized solutions, ensuring each case is handled with precision and care to achieve the best possible outcomes for its clients.

Media Contact
Company Name: Mokolo Law Firm, PLLC
Contact Person: Uzo Mokolo
Email: Send Email
Phone: (713) 784-2906
Address:6464 Savoy Dr Suite 570
City: Houston
State: TX
Country: United States
Website: http://www.mokololaw.com/